360b / Shutterstock.com
The English High Court has ordered Novartis to pay 75% of the defendants’ legal costs in a patent infringement case against Focus Pharmaceuticals, Actavis and Teva.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
English High Court, Novartis, Exelon, costs, Focus Pharmaceuticals, Actavis, Teva; rivastigmine